Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Chong Kun Dang Pharmaceutical Corp.
DescriptionNot disclosed
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase II
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today